Literature DB >> 35702492

Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors.

Rita K Schmutzler1, Björn Schmitz-Luhn2, Bettina Borisch3, Peter Devilee4, Diana Eccles5, Per Hall6, Judith Balmaña7, Stefania Boccia8,9, Peter Dabrock10, Günter Emons11, Wolfgang Gaissmaier12, Jacek Gronwald13, Stefanie Houwaart14, Stefan Huster15, Karin Kast1, Alexander Katalinic16, Sabine C Linn17, Sowmiya Moorthie18, Paul Pharoah19, Kerstin Rhiem1, Tade Spranger20, Dominique Stoppa-Lyonnet21, Johannes Jozef Marten van Delden22, Marc van den Bulcke23, Christiane Woopen2.   

Abstract

Background: Risk-adjusted cancer screening and prevention is a promising and continuously emerging option for improving cancer prevention. It is driven by increasing knowledge of risk factors and the ability to determine them for individual risk prediction. However, there is a knowledge gap between evidence of increased risk and evidence of the effectiveness and efficiency of clinical preventive interventions based on increased risk. This gap is, in particular, aggravated by the extensive availability of genetic risk factor diagnostics, since the question of appropriate preventive measures immediately arises when an increased risk is identified. However, collecting proof of effective preventive measures, ideally by prospective randomized preventive studies, typically requires very long periods of time, while the knowledge about an increased risk immediately creates a high demand for action. Summary: Therefore, we propose a risk-adjusted prevention concept that is based on the best current evidence making needed and appropriate preventive measures available, and which is constantly evaluated through outcome evaluation, and continuously improved based on these results. We further discuss the structural and procedural requirements as well as legal and socioeconomical aspects relevant for the implementation of this concept.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Breast cancer; ELSI ethical, legal, social implications; Evidence-generating care; Risk-adjusted prevention

Year:  2021        PMID: 35702492      PMCID: PMC9149472          DOI: 10.1159/000517182

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.268


  66 in total

Review 1.  Interventions to improve risk communication in clinical genetics: systematic review.

Authors:  A Edwards; J Gray; A Clarke; J Dundon; G Elwyn; C Gaff; K Hood; R Iredale; S Sivell; C Shaw; H Thornton
Journal:  Patient Educ Couns       Date:  2008-01-18

2.  Public health implications from COGS and potential for risk stratification and screening.

Authors:  Hilary Burton; Susmita Chowdhury; Tom Dent; Alison Hall; Nora Pashayan; Paul Pharoah
Journal:  Nat Genet       Date:  2013-04       Impact factor: 38.330

3.  Genetic education and the challenge of genomic medicine: development of core competences to support preparation of health professionals in Europe.

Authors:  Heather Skirton; Celine Lewis; Alastair Kent; Domenico A Coviello
Journal:  Eur J Hum Genet       Date:  2010-05-05       Impact factor: 4.246

4.  Preparing clinicians for genomic medicine.

Authors:  Ingrid Slade; Hilary Burton
Journal:  Postgrad Med J       Date:  2016-03-21       Impact factor: 2.401

Review 5.  Modifiers of risk of hereditary breast cancer.

Authors:  S A Narod
Journal:  Oncogene       Date:  2006-09-25       Impact factor: 9.867

6.  Using a drug facts box to communicate drug benefits and harms: two randomized trials.

Authors:  Lisa M Schwartz; Steven Woloshin; H Gilbert Welch
Journal:  Ann Intern Med       Date:  2009-02-16       Impact factor: 25.391

7.  Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.

Authors:  Bernadette A M Heemskerk-Gerritsen; Matti A Rookus; Cora M Aalfs; Margreet G E M Ausems; Johanna M Collée; Liesbeth Jansen; C Marleen Kets; Kristien B M I Keymeulen; Linetta B Koppert; Hanne E J Meijers-Heijboer; Thea M Mooij; Rob A E M Tollenaar; Hans F A Vasen; Maartje J Hooning; Caroline Seynaeve
Journal:  Int J Cancer       Date:  2014-07-08       Impact factor: 7.396

8.  Gene-panel sequencing and the prediction of breast-cancer risk.

Authors:  Douglas F Easton; Paul D P Pharoah; Antonis C Antoniou; Marc Tischkowitz; Sean V Tavtigian; Katherine L Nathanson; Peter Devilee; Alfons Meindl; Fergus J Couch; Melissa Southey; David E Goldgar; D Gareth R Evans; Georgia Chenevix-Trench; Nazneen Rahman; Mark Robson; Susan M Domchek; William D Foulkes
Journal:  N Engl J Med       Date:  2015-05-27       Impact factor: 91.245

Review 9.  Incorporating genomics into breast and prostate cancer screening: assessing the implications.

Authors:  Susmita Chowdhury; Tom Dent; Nora Pashayan; Alison Hall; Georgios Lyratzopoulos; Nina Hallowell; Per Hall; Paul Pharoah; Hilary Burton
Journal:  Genet Med       Date:  2013-02-14       Impact factor: 8.822

Review 10.  Evidence for Health III: Making evidence-informed decisions that integrate values and context.

Authors:  Anne Andermann; Tikki Pang; John N Newton; Adrian Davis; Ulysses Panisset
Journal:  Health Res Policy Syst       Date:  2016-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.